LANDOS BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.31 USD | -0.80% |
|
+2.25% | +509.56% |
| 04-02 | North American Morning Briefing : Stocks Seen -2- | DJ |
| 04-01 | HC Wainwright Downgrades Landos Biopharma to Neutral From Buy | MT |
Chart calendar Landos Biopharma, Inc.
83a5f5f2f2f5c55da0cad27f0fb42.3ObcnyEyr72AXWQAJZRh9M9x7Ne3rJpu1l8y7nWN070.5bSMzWJ84O2wC1ZEVssgl6EBtOTe7-wKkjQLojLX6ujohfHPYGDI8cMrMQ~1fd614b28e3a7ec1e49d1e01a9a3912f
Upcoming events on Landos Biopharma, Inc.
Past events on Landos Biopharma, Inc.
| 21/03/2024 12:00 | Q4 2023 Earnings Release |
| 22/02/2024 | European Crohn and Colitis Organisation Congress - Poster number: P739 |
| 22/02/2024 | European Crohn and Colitis Organisation Congress - Poster number: P144 |
| 22/02/2024 | European Crohn and Colitis Organisation Congress - Poster number: P114 |
| 22/02/2024 | European Crohn and Colitis Organisation Congress - Poster number: P571 |
| 22/02/2024 | European Crohn and Colitis Organisation Congress - Poster number: P086 |
| 22/02/2024 | European Crohn and Colitis Organisation Congress - Poster number: P077 |
| 09/11/2023 13:00 | Q3 2023 Earnings Release |
| 24/10/2023 18:30 | American College of Gastroenterology Scientific Meeting - Poster Number : P3644 |
| 24/10/2023 18:30 | American College of Gastroenterology Scientific Meeting - Poster Number : P3548 |
| 24/10/2023 18:30 | American College of Gastroenterology Scientific Meeting - Poster Number : P3607 |
| 16/10/2023 13:30 | United European Gastroenterology Conference - The new kids on the block in IBD: Part 2 |
| 16/10/2023 10:30 | United European Gastroenterology Conference - The new kids on the block in IBD: Part 1 |
| 09/08/2023 13:00 | Q2 2023 Earnings Release |
| 09/06/2023 14:00 | Jefferies Healthcare Conference |
| 23/05/2023 14:00 | Annual General Meeting |
| 12/05/2023 13:00 | Q1 2023 Earnings Release |
| 23/03/2023 12:00 | Q4 2022 Earnings Release |
| 28/02/2023 | ECCO Congress |
| 05/01/2023 13:00 | Business Update Call |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 18,0 18,0 0% | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -30,5 -28,0 -9.07% | -38,6 -30,0 -28.73% | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -13,3 | -30,7 -25,7 -19.35% | -38,8 -32,3 -20.1% | -40,6 -42,0 3.43% | 0,00 0,00 - | -26,4 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -30,1 -25,0 -20.39% | -38,4 -33,3 -15.33% | -39,3 -41,8 6.05% | 0,00 0,00 - | -26,4 |
|
Net income Million USD | Released Forecast Spread | 0,00 | -30,1 -25,0 -20.39% | -38,4 -33,2 -15.74% | -39,3 -41,8 6.04% | -21,9 -21,4 -2.5% | -26,4 |
|
EPS USD | Released Forecast Spread | -21,6 | -24,7 -20,8 -19.04% | -10,2 -8,96 -13.84% | -9,80 -9,83 0.34% | -3,50 -3,41 -2.64% | -2,35 |
| Announcement Date | 24/07/20 | 31/03/21 | 24/03/22 | 23/03/23 | 21/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -20,3 -12,0 -69.51% | ||||||||||||
|
EBIT Million USD | Released Forecast Spread | -20,4 -13,7 -48.62% | -15,0 -14,9 -0.57% | -11,3 -15,0 24.98% | -7,83 -11,5 32.03% | -6,51 -7,98 18.34% | -6,48 -7,00 7.44% | -5,50 | -6,40 | -6,90 | -7,60 | |||
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -20,1 -14,2 -41.98% | -14,9 -15,4 3.38% | -11,3 -14,6 22.56% | -7,90 -11,5 31.14% | -5,23 -7,93 34.03% | -6,03 -7,00 13.8% | -5,50 | -6,40 | -6,90 | -7,60 | |||
|
Net income Million USD | Released Forecast Spread | -20,1 -14,1 -42.09% | -14,9 -15,4 3.38% | -11,3 -14,6 22.56% | -7,90 -11,4 30.8% | -5,23 -7,89 33.67% | -6,03 -7,00 13.8% | -3,92 -6,60 40.58% | -5,86 -4,90 -19.59% | -6,12 -5,60 -9.27% | -5,50 | -6,40 | -6,90 | -7,60 |
|
EPS USD | Released Forecast Spread | -5,20 -3,54 -46.93% | -3,70 -3,47 -6.54% | -2,80 -3,65 23.29% | -2,00 -2,83 29.41% | -1,30 -1,70 23.53% | -0,90 -1,00 10% | -0,63 -1,10 42.73% | -0,94 -0,79 -18.99% | -1,84 -0,91 -102.2% | -0,88 | -0,63 | -0,48 | -0,53 |
| Announcement Date | 24/03/22 | 12/05/22 | 11/08/22 | 10/11/22 | 23/03/23 | 12/05/23 | 09/08/23 | 09/11/23 | 21/03/24 | - | - | - | - |
| Today 21:05 | QIAGEN N.V.: Q1 2024 Earnings Release |
| 29/04/2024 | CRISPR THERAPEUTICS AG: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | PROTAGONIST THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | EDITAS MEDICINE, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | AZENTA, INC.: Q2 2024 Earnings Release (Projected) |
| 01/05/2024 11:30 | UNITED THERAPEUTICS CORPORATION: Q1 2024 Earnings Release |
| 01/05/2024 11:30 | BIO-TECHNE CORPORATION: Q3 2024 Earnings Release |
| 01/05/2024 12:00 | ALKERMES PLC: Q1 2024 Earnings Release |
| 01/05/2024 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
Past sector events for Landos Biopharma, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- LABP Stock
- Calendar Landos Biopharma, Inc.
